look I definitely agree that it’s a good decision, but the setback on income is immense in my opinion.
unless as I mentioned, the potential was never there due to issues that were kept in the dark.
either way the only positive to come out of this is a ceo who can make quick decisions.
Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-49
-
- There are more pages in this discussion • 147 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.003(10.3%) |
Mkt cap ! $64.73M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.0¢ | 2.6¢ | $209.8K | 7.543M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 592714 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 269442 | 1 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| ADO (ASX) Chart |